CCR5 and breast cancer: CCR5 antagonists slow the invasion of basal breast carcinoma cells in vitro and decrease pulmonary metastasis in a preclinical mouse model of breast cancer, suggesting that CCR5 antagonists can be used as adjuvant therapy in patients with this breast cancer subtype [51].